

SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME MOMETASONE FUROATE, USP

PRODUCT CODE 2413

SUPPLIER MEDISCA Inc.

Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901

3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118

6641 N. Belt Line Road, Suite 130, Irving, TX, 75063

MEDISCA Pharmaceutique Inc.

Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8

21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2

MEDISCA Australia PTY LTD

Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047

Unit 7, Heritage Business Park

5-9 Ricketty Street, Mascot, NSW 2020

EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300

NSW Poisons Information Centre: 131 126

USES Corticosteroid (Topical); Anti-Inflammatory Agent; Anti-allergic Agent

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION Acute Toxicity - Oral (Category 5)

Toxic to Reproduction (Category 2)

Chronic Aquatic Toxicity (Category 2)

Specific Target Organ Toxicity - Repeated Exposure (Category 1) - (endocrine system)

PICTOGRAM





SIGNAL WORD

HAZARD STATEMENT(S)

Danger

May be harmful if swallowed.

May cause an allergic reaction.

Suspected of damaging fertility or the unborn child.

Causes damage to organs through prolonged or repeated exposure.

Toxic to aquatic life with long lasting effects

AUSTRALIA-ONLY HAZARDS

PRECAUTIONARY STATEMENT(S)

Not Applicable.

Prevention Do not breathe dust/fume/gas/mist/ vapors/spray.

Contaminated work clothing must not be allowed out of the workplace.

Obtain special instructions before use.

Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing, eye protection, face protection.

Wash thoroughly after handling.

Do not eat, drink or smoke when using this product.

Avoid release to the environment.

Response IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical

advice/attention. Wash contaminated clothing before reuse. IF EXPOSED OR CONCERNED: Get medical advice/attention.

COLLECT SPILLAGE

Storage Store locked up.



Disposal Dispose of contents and/or container in accordance with local regulations.

HMIS CLASSIFICATION Health Hazard 1 Flammability 0

Reactivity 0 Personal Protection G

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

CHEMICAL NAME
Pregna-1, 4-diene-3, 20-dione, 9, 21-dichloro-17-[(2-furanylcarbonyl) oxy]-11-hydroxy-16-methyl-, (11β, 16α)-.

BOTANICAL NAME

SYNONYM

Not applicable

Not applicable

CHEMICAL FORMULA

C27H30Cl2O6

CAS NUMBER

83919-23-7

ALTERNATE CAS NUMBER

Not applicable

MOLECULAR WEIGHT 521.434

COMPOSITION CHEMICAL NAME CAS NUMBER % BY WEIGHT
MOMETASONE FUROATE 83919-23-7 100

There are no additional ingredients present which, within the current knowledge of the supplier and in the

concentrations applicable, are classified as health hazards and hence require reporting in this section.

NOTES Chemical family: Corticosteroid.

SECTION 4: FIRST-AID MEASURES

IN CASE OF EYE CONTACT Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek

medical aid.

IN CASE OF SKIN CONTACT

Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a

physician

SYMPTOMS AND EFFECTS Not expected to present a significant hazard under anticipated conditions of normal use.

SECTION 5: FIREFIGHTING MEASURES

SPECIFIC HAZARDS ARISING FROM

THE CHEMICAL

FLAMMABLE PROPERTIES

HAZARDOUS COMBUSTION PRODUCTS

EXTINGUISHING MEDIA

Not applicable.

May be combustible at high temperature.

Under fire conditions, hazardous fumes will be present.

Small fire: dry chemical, CO2 or water spray. Large fire: dry chemical, CO2, alcohol resistant foam or water

spray. Do not get water inside containers.

PROTECTIVE EQUIPMENT AND
Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

PRECAUTIONS FOR FIREFIGHTERS

SECTION 6: ACCIDENTAL RELEASE MEASURES

Last Revision: 11/2018 MOMETASONE FUROATE, USP Page 2 of 7



PERSONAL PRECAUTIONS

Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

METHODS & MATERIAL FOR CONTAINMENT

CLEANUP PROCEDURE

On land, sweep or shovel into suitable containers. Minimize generation of dust.

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible

vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean

the affected area. Do not flush into sewerage system or to drains.

SECTION 7: HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash

thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabelled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use

appropriate containment to avoid environmental contamination.

STORAGE CONDITIONS Store in original container, tightly sealed, protected from direct sunlight and moisture.

Preserve in well-closed containers.

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Chemical Name: MOMETASONE FUROATE CAS #: 83919-23-7

	TWA	Ceiling	STEL	REL	IDLH	Remarks
OSHA PEL	N/L	N/L	-	-	-	-
ACGIH TLV	N/L	N/L	N/L	-	-	-
NIOSH	N/L	N/L	N/L	N/L	N/L	-
AIHA WEEL	N/L	N/L	N/L	-	-	-
Safe Work Australia HSIS	N/L	N/L	N/L	-	-	-
HSE	N/L	N/L	N/L	-	-	-

N/L = Not Listed

EXPOSURE GUIDELINESConsult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable

fraction: 5 mg/m³

PERSONAL PROTECTIVE EQUIPMENT

Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate

gloves to prevent skin exposure. **Clothing:** Wear appropriate protective clothing to minimize contact with skin. **Respirators:** Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are

exceeded or if irritation or other symptoms are experienced.

SPECIFIC ENGINEERING CONTROLS Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

NOTES Potent pharmacologically active material. Occupational exposure to small amounts may cause physiological

effects.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

Solid

Last Revision: 11/2018 MOMETASONE FUROATE, USP Page 3 of 7



Not available

DESCRIPTION White to off-white powder.

Practically insoluble in water; freely soluble in alcohol and in acetone; sparingly soluble in propylene glycol. SOLUBILITY

EVAPORATION RATE

ODOR Odorless

FLAMMABILITY May be combustible at high temperature

Not available

ODOR THRESHOLD MELTING POINT Not available pΗ Not available (215 - 228)°C, (419-442.4)°F

BOILING POINT FREEZING POINT FLASH POINT Not available (215 - 228)°C, Not available

(419-442.4)°F

Not available

SPECIFIC GRAVITY **EXPLOSIVE LIMIT**

UPPER FLAMMABLE/ Not available LOWER FLAMMABLE/ Not available **VAPOR PRESSURE** Not available EXPLOSIVE LIMIT(S) EXPLOSIVE LIMIT(S)

VAPOR DENSITY Not available **RELATIVE DENSITY** Not available log P 4.115 (20°C) (OCTANOL-WATER)

(AIR = 1)(WATER = 1)

AUTO-IGNITION Not available **DECOMPOSITION** VISCOSITY Not available Not available **TEMPERATURE** TEMPERATURE

NOTES The physical data presented above are typical values and should not be construed as a specification.

SECTION 10: STABILITY AND REACTIVITY

REACTIVITY Not established.

STABILITY Stable under recommended storage conditions.

MATERIALS TO AVOID Strong oxidants.

HAZARDOUS DECOMPOSITION Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur.

PRODUCTS

HAZARDOUS POLYMERIZATION Will not occur.

Not established. POSSIBLITY OF HAZARDOUS

REACTION

IRRITATION

CONDITIONS TO AVOID Moisture, sunlight and extreme temperatures.

SECTION 11: TOXICOLOGICAL INFORMATION

ACUTE TOXICITY Oral: Rat: LD50: (mg/kg): >2000

> Dermal: Rabbit LD50: (mg/kg): Not available Inhalation: Rat: LC50: (mg/L/4hr): Not available

SKIN CORROSION/IRRITATION Based on available data, the classification criteria are not met.

SERIOUS EYE DAMAGE/EYE Based on available data, the classification criteria are not met.



RESPIRATORY OR SKIN SENSITIZATION

Respiratory sensitization: Due to lack of data the classification is not possible.

Skin sensitization: Based on available data, the classification criteria are not met. Suspected skin sensitiser: The Toolbox profiler Protein binding alerts for skin sensitization by OASIS v1.3 gives an alert for skin

sensitisation

GERM CELL MUTAGENICITY

Based on available data, the classification criteria are not met.

Suspected mutagen: The Toolbox profiler in vitro mutagenicity (Ames test) alerts by ISS gives an alert for mutagenicity; The Toolbox profiler Protein binding alerts for Chromosomal aberration by OASIS v1.1 gives an

alert for mutagenicity

CARCINOGENICITY

OSHA MOMETASONE FUROATE is not listed.

MOMETASONE FUROATE is not listed.

IARC MOMETASONE FUROATE is not evaluated.

California Proposition 65

NTP

This product does not contain any chemicals known to the State of California to cause

cancer, birth defects, or any other reproductive harm.

ADDITIONAL CARCINOGENICITY INFORMATION

Based on available data, the classification criteria are not met.

Suspected carcinogen: The Toolbox profiler Carcinogenicity (genotox and nongenotox) alerts by ISS gives an alert for carcinogenicity; ISS Carcinogenicity model in VEGA (Q)SAR platform predicts that the chemical is

Carcinogen (good reliability).

REPRODUCTIVE TOXICITY

Suspected of damaging fertility or the unborn child.

Most studies have concluded that therapeutic use of corticosteroids by pregnant women does not cause adverse effects on the fetus. A small increase in the incidence of cleft palate was seen in some human studies. Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be observed for signs of hypoadrenalism. Corticosteroids have been shown to cause birth defects in laboratory animals when administered systemically at low doses, and some caused birth defects when administered topically.

Suspected toxic for reproduction: CAESAR developmental toxicity model in VEGA (Q)SAR platform predicts that the chemical is Toxicant (moderate reliability).

SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE

Based on available data, the classification criteria are not met.

SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE

ASPIRATION HAZARDS

SIGNS AND SYMPTOMS OF EXPOSURE

Based on available data, the classification criteria are not met.

Potent pharmacologically active material. Occupational exposure to small amounts may cause physiological effects.

Symptoms related to the physical, chemical, and toxicological characteristics:

Causes damage to organs (endocrine system) through prolonged or repeated exposure.

Mineralocorticoid effects: Swelling. Confusion. Lightheadedness. Nausea. Vomiting. Numbness. Tremors. Glucocorticoid effects: Bone fractures. Back pain. Joint pain or stiffness. Weakness. Increased appetite. Infection. Delayed wound healing. Thinning skin. Bruising. Purple lines on skin. Increased hair growth. Acne. Redistribution of body fat. Menstrual irregularities. Impotence. Headache. Increased sweating. Eye pain. Change in vision. Mental or behavioral changes. Withdrawal effects: Fever. Muscle pain. Joint pain. Malaise.

Delayed and immediate effects of exposure:

Corticosteroids: Fluid and electrolyte imbalance. Cushing's syndrome. Adrenal suppression. Immune system depression. Withdrawal.

Cross sensitivity:

Persons sensitive to one corticosteroid may be sensitive to this material also.

Medical conditions aggravated by exposure:

Corticosteroids: Heart disease. High blood pressure. Diabetes. Epilepsy. Glaucoma. Hypothyroidism. Osteoporosis. Peptic ulcer. Systemic fungal infection. Mental disorders. Impaired liver or kidney function.

POTENTIAL HEALTH EFFECTS

Inhalation

May be harmful if inhaled. May cause respiratory tract irritation.

Last Revision: 11/2018 MOMETASONE FUROATE, USP Page 5 of 7



Ingestion Ingestion is not a significant route of occupational overexposure. Acute ingestion of large

quantities of this product or chronic ingestion caused by poor hygiene practices may cause adverse symptoms. Symptoms of ingestion overexposure may include nausea, vomiting, and

diarrhea.

Skin May cause skin irritation. May cause allergic reaction. Mometasone Furoate can be

absorbed through intact skin. Symptoms of chronic overexposure by this route may include reversible hypothalamic-pituitaryadrenal (HPA) axis suppression, abnormal accumulations of facial and trunk fat, fatigue, high blood pressure, osteoporosis, abnormally high level of

glucose in the blood, and abnormally high levels of glucose in the urine.

Eyes May cause eye irritation.

SECTION 12: ECOLOGICAL INFORMATION

TOXICITY EC50: 48 Hr: Crustacea: (mg/L): Not available

LC50: 96 Hr: Fish: (mg/L): < 1*

EC50: 96 Hr: Green algae: (mg/L): < 1*

PERSISTENCE AND DEGRADABILITY Suspected persistent in the environment: The Danish QSAR database contains information indicating that the

substance is predicted as non readily biodegradable.

BIOACCUMULATIVE POTENTIAL High: LogPow: 4.115 (20°C)

MOBILITY IN SOIL Practically insoluble in water. (< 1 mg/L)

OTHER ADVERSE EFFECTS Not available

This product is not intended to be released into the environment.

NOTES *Danish QSAR database

SECTION 13: DISPOSAL CONSIDERATIONS

WASTE DISPOSAL Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

SECTION 14: TRANSPORT INFORMATION

UNITED STATES & CANADA

UN PROPER SHIPPING NAME Not dangerous good

Not applicable

UN NUMBER Not applicable
CLASS Not applicable

PACKING GROUP

AUSTRALIA

UN PROPER SHIPPING NAME

Not dangerous good

UN NUMBER Not applicable
CLASS Not applicable
PACKING GROUP Not applicable
HAZCHEM Not applicable

ENVIRONMENTAL HAZARDS Not available



SPECIAL SHIPPING INFORMATION

Not applicable

SECTION 15: REGULATORY INFORMATION

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR Part 372.65	EPA 40 CF Appendix A	FR Part 355 Appendix B	Pennsylvania	Right-to-know New Jersey	Massachusetts	California Prop 65
MOMETASONE FUROATE 83919-23-7	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

AUSTRALIAN REGULATIONS

Chemical Name & CAS	Poisons and Therapeutic Goods Regulation	Therapeutic Goods Act	Code of Practices - Illicit Drug Precursors	
MOMETASONE FUROATE	N/L	Listed as Schedule 4	N/L	
83919-23-7				

SECTION 16: OTHER INFORMATION

REFERENCES

ABBREVIATIONS AND ACRONYMS

Available upon request

CAS – Chemical Abstract Service; GHS – Global Harmonized System; OSHA PEL – Occupational Safety & Health Administration Permissible Exposure Limits; TWA – Time Weighted Average; HSIS – Hazardous Substances Information System; STEL – Short Term Exposure Limit; AlHA WEEL – American Industrial Hygiene Association Workplace Environment Exposure Levels; LD50 – Lethal Dose, 50%; IARC – International Agency for Research on Cancer; NTP – National Toxicology Program; WHMIS – Workplace Hazardous Materials Information System; SARA – Superfund Amendments and Reauthorization Act; EPA – Environmental Protection Agency; CERCLA – Comprehensive Environmental Response, Compensation, and Liability Act; HMIS – Hazardous Materials Information System; NIOSH – National Institute for Occupational Safety and Health; MSHA - Mine Safety and Health Administration; ACGIH - American Conference of Governmental Industrial Hygienists; IDHL - Immediately Dangerous to Health or Life; TLV – Threshold Limit Value; HSE – Health and Safety Executive; REL - Recommended Exposure Limit

LAST REVISION SUPERSEDES

DISCLAIMER

11/2018

07/2015

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.